See more from Highlights from ACG 2014
PHILADELPHIA — In this exclusive video interview, Paul Y. Kwo, MD, professor of medicine, Indiana University, discusses the new and upcoming therapies, including the recently approved combination regimen of ledipasvir and sofosbuvir, to treat patients with hepatitis C virus infection. He further discusses how the new therapies will impact patients within this specific population in the future.
“With a lot of hard work, we should be able to successfully treat and eradicate this disease within the next several decades,” Kwo said.
Disclosure: Kwo holds multiple advisory roles and has received grant support from multiple pharmaceutical companies
“With a lot of hard work, we should be able to successfully treat and eradicate this disease within the next several decades,” Kwo said.
Disclosure: Kwo holds multiple advisory roles and has received grant support from multiple pharmaceutical companies
This is your central portal for information presented at the American College of Gastroenterology's Annual Scientific Meeting, including the latest data on novel treatment options and results from important clinical trials. In addition to breaking news, this resource page features onsite video interviews with leading experts to get their reactions to some of the clinical updates and news presented at the conference, and what implications this research may have for the future.
No comments:
Post a Comment